There are actually 7 PARP inhibitors in development.
The other two are INO-001, which is being tested in acute myocardial infarction and CEP-9722, which is being tested in cancer.
The mysterious 8th one, if you wade through the link to the clinical trials, is bardoxolone, which is not a PARP inhibitor, but an antioxidant inflammation modulator or AIM for short.
Sallyof NJ7:48PM February 28, 2010
Does anyone know if Parp Inhibitors are being used in maintainence trials yet. l know they are used as part of treatment but l'm looking for one after treatment.
l am a BRCA 1 Ovarian Cancer
Luckyx49:41AM January 22, 2010
I would also be interested in knowing what the others, are, too. I also know of the five mentioned by Bill in FL.
Thank you!
Tinaof NV10:54PM January 21, 2010
I know of 5 Parp Inhibitor agents currently in clinical trails, Bipar Sciences (BSI-201), Abbott (ABT-888),Astra Zeneca (AZD2281/KU-0059436), Merck (MK4827) and Pfizer (AG014699). The article mentions that there are at least eight that are being developed. What are the others?
Get answers to your health questions from 10 leaders in health and medical fields, from cardiology to integrative medicine and women's health to fitness and nutrition.
Reader Comments
Back to blog
Sally of NJ 7:48PM February 28, 2010
Luckyx4 9:41AM January 22, 2010
Tina of NV 10:54PM January 21, 2010
Bill of FL 4:24PM January 19, 2010